Aging, energy, and oxidative stress in neurodegenerative diseases

Annals of Neurology

Volumn 38, Issue 3, 1995, Pages 357-366

  Beal, M Flint ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

21 AMINOSTEROID; 7 NITROINDAZOLE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIOXIDANT; CALCIUM; DIHYDROLIPOATE; EXCITATORY AMINO ACID RECEPTOR; FIBROBLAST GROWTH FACTOR; FREE RADICAL; GLUTAMATE RECEPTOR ANTAGONIST; INDAZOLE DERIVATIVE; KAINIC ACID; LAMOTRIGINE; MITOCHONDRIAL DNA; MITOCHONDRIAL ENZYME; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N TERT BUTYL ALPHA PHENYLNITRONE; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NICOTINAMIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHENCYCLIDINE; QUISQUALIC ACID; RILUZOLE; SCAVENGER; SOMATOMEDIN B; UBIDECARENONE;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; DEGENERATIVE DISEASE; DEPOLARIZATION; DOSE RESPONSE; ENERGY METABOLISM; ENZYME ACTIVITY; HUMAN; HUNTINGTON CHOREA; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STROKE;

AGING; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; ENERGY METABOLISM; HUMAN; HUNTINGTON DISEASE; MITOCHONDRIA; NERVE DEGENERATION; NERVOUS SYSTEM DISEASES; OXIDATIVE STRESS; RECEPTORS, N-METHYL-D-ASPARTATE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029125857     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410380304     Document Type: Article

References (117)

1. Alternative excitotoxic hypotheses
2. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
3. Glutamate becomes neurotoxic via the N‐methyl‐D‐asparatate receptor when intracellular energy levels are reduced
4. Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor‐mediated toxicity in retina
5. 2+ accumulation in cortical cell culture correlates with subsequent neuronal degeneration
6. 2+ chelators reduce early excitotoxic and ischemic neuronal injury in vitro and in vivo
7. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons
8. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures
9. Mechanisms of nitric oxide mediated neurotoxicity in primary brain cultures
10. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase
11. NMDA‐dependent superoxide production and neurotoxicity
12. Oxidative stress induced by glutamate receptor agonists
13. Reduced neurotoxicity in transgenic mice overexpressing human copper‐zinc‐superoxide dismutase
14. ·‐ in the production of HO·: in vitro and in vivo
15. Pathological implications of nitric oxide, superoxide and peroxynitrite formation
16. Absence of electron transport (Rho° State) restores growth of a manganesesuperoxide dismutase‐deficient Saccharomyces cerevisiae in hyperoxia
17. The mitochondrial generation of hydrogen peroxide
18. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria
19. Ubisemiquinones as obligatory intermediates in the electron transfer from NADH to ubiquinone
20. 2 in brain mitochondria
21. Mitochondria buffer physiological calcium loads in cultured rat dorsal root ganglion neurons
22. +: implications for neurodegeneration
23. Imaging of mitochondrial oxygen radical production in cortical neurons exposed to NMDA
24. Normal oxidative damage to mitochondrial and nuclear DNA is extensive
25. Oxidative damage to mitochondrial DNA shows marked age‐dependent increases in human brain
26. Age‐dependent impairment of mitochondrial function in primate brain
27. Age‐dependent changes in mitochondrial energy production in striatum and cerebellum of the monkey brain
28. Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of aging
29. Decline with age of the respiratory chain activity in human skeletal muscle
30. Detection of a specific mitochondrial DNA deletion in tissues of older humans
31. Hypoxemia is associated with mitochondrial DNA damage and geneinduction
32. Accumulation of deletions in human mitochondrial DNA during normal aging: analysis by quantitative PCR
33. Age‐dependent increase in deleted mitochondrial DNA in the human heart: possible contributory factor to presbycardia
34. Quantitative analysis of age‐associated accumulation of mitochondrial DNA with deletion in human hearts
35. Age‐dependent increase of mitochondrial DNA deletions together with lipid peroxides and superoxide dismutase in human liver mitochondria
36. Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain
37. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age
38. Differential accumulations of 4,977 bp deletion in mitochondrial DNA of various tissues in human ageing
39. The point mutation of mitochondrial DNA characteristic for MERRF disease is found also in healthy people of different ages
40. Occurrence of a particular base substitution (3243 A to G) in mitochondrial DNA of tissues of ageing humans
41. Age‐associated accumulation of 8‐hydroxydeoxyguanosine in mitochondrial DNA of human diaphragm
42. Age‐associated oxygen damage and mutations in mitochondrial DNA in human hearts
43. Rapid ATP loss caused by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in mouse brain
44. 1‐Methyl‐4‐phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism
45. MK‐801 prevents 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced parkinsonism in primates
46. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP‐induced degeneration in primates
47. 3‐Acetylpyridine‐induced degeneration of the nigrostriatal dopamine system: an animal model of olivopontocerebellar atrophy‐associated parkinsonism
48. 3‐Acetylpyridine produces age‐dependent excitotoxic lesions in rat striatum
49. Age‐dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate
50. Inhibition of succinate dehydrogenase by malonic acid produces an “excitotoxic” lesion in rat striatum
51. Malonate produces striatal lesions by indirect NMDA receptor activation
52. 3‐Nitropropionic acid—exogenous animal neurotoxin and possible human striatal toxin
53. Inhibition of energy metabolism by 3‐nitropropionic acid activates ATP‐sensitive potassium channels
54. 3‐Nitropropionic acid decreases cellular energy levels and causes neuronal degeneration in cortical explants
55. 3‐Nitropropionic acid is an indirect excitotoxin to cultured cerebellar granule neurons
56. Age‐dependent vulnerability of the striatum to the mitochondrial toxin 3‐nitropropionic acid
57. Neurochemical and histologic characterization of striatal excitoxic lesions produced by the mitochondrial toxin 3‐nitropropionic acid
58. 3‐Nitropropionic acid toxicity in the striatum
59. Chronic administration of 3‐nitropropionic acid induced selective striatal degeneration and abnormal choreiform movements in monkeys
60. Transgenic mice with increased Cu/Zn‐superoxide dismutase activity are resistant to N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine induced neurotoxicity
61. Inhibition of neuronal nitric oxide synthase by 7‐nitroindazole protects against MPTP‐induced neurotoxicity in mice
62. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
63. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase
64. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyortrophic lateral sclerosis
65. ALS, SOD and peroxynitrite
66. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation
67. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons
68. 1 reductase (complex I) deficiency in Parkinson's disease
69. Unaltered aconitase activity, but decreased complex I activity in substantia nigrapars compacta of patients with Parkinson's disease
70. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease
71. Abnormalities of the electron transport chain in idiopathic Parkinson's disease
72. Low platelet mitochon drial complex I activity in untreated early Parkinson disease
73. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson‐plus syndromes
74. Cortical glucose metabolism in Parkinson's disease without dementia
75. Evidence for impairment of energy metabolim in Parkinson's disease using in vivo localized MR spectroscopy
76. Mitochondrial DNA mutations associated with Alzheimer's and Parkinson's disease
77. Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra: an HPLC and ESR study
78. A marker of oxyradical‐mediated DNA damage (8‐hydroxy‐2′deoxyguanosine) is increased in nigro‐striatum of Parkinson's disease brain
79. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
80. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
81. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease
82. Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy
83. Evidence for a metabolic disorder in Huntington's disease
84. Cytochrome oxidase deficiency in Alzheimer's disease
85. Brain cytochrome oxidase in Alzheimer's disease
86. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease
87. Electron transport chain defects in Alzheimer's disease brain
88. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease
89. Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in hippocampal formation
90. Localization of cytochrome oxidase (COX) activity and COX mRNA in the hippocampus and entorhinal cortex of the monkey brain: correlation with specific neuronal pathway
91. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro
92. Brain membrane fluidity and lipid peroxidation in Alzheimer's disease
93. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease
94. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease
95. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease
96. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress
97. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease
98. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative
99. Amyloidogenicity of rodent and human βA4 sequences
100. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform‐specific effects and implications for late‐onser Alzheimer disease
101. A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia
102. The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease
103. A controlled trial of riluzole in amyotrophic lateral sclerosis
104. Excitatory amino acids as a final common pathway for neurologic disorders
105. Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria
106. Ubiquinone protects cultured neurons against spontaneous and excitotoxin‐induced degeneration
107. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
108. Ubiquinone lowers occipital lactate levels in patients with Huntington's disease
109. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusioninduced injury to gerbil brain
110. α‐Phenyl‐tert‐butyl‐nitrone reduces cortical infarct and edema in rats subjected to focal ischemia
111. Cerebral ischemia, free radicals and antioxidant protection
112. The endogenous cofactors, thioctic acid and dihydrolipoic acid, are neuroprotective against NMDA and malonic acid lesions of striatum
113. Growth factors prevent mitochondrial dysfunction, loss of calcium homeostasis, and cell injury, but not ATP depletion in hippocampal neurons deprived of glucose
114. Basic FGF, NGF, and IGFs protect hippocampal and cortical neurons against iron‐induced degeneration